Neuland Laboratories is currently trading at Rs. 1510.00, down by 15.80 points or 1.04% from its previous closing of Rs. 1525.80 on the BSE.
The scrip opened at Rs. 1499.95 and has touched a high and low of Rs. 1561.15 and Rs. 1446.50 respectively. So far 15,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1680.00 on 05-Apr-2017 and a 52 week low of Rs. 678.00 on 10-May-2016.
Last one week high and low of the scrip stood at Rs. 1680.00 and Rs. 1446.50 respectively. The current market cap of the company is Rs. 1,341.52 crore.
The promoters holding in the company stood at 51.68%, while Institutions and Non-Institutions held 15.85% and 32.47% respectively.
Neuland Laboratories’ manufacturing facility at Bonthapally, Hyderabad has been audited by the United States Food and Drug Administration (USFDA) from April 3-7, 2017. At the end of the inspection, there were 2 observations given under form 483.
The two observations relates to procedures followed for the annual quality standards record evaluation and cleaning and maintenance of equipment at appropriate intervals during manufacturing campaign. The company has already initiated corrective and preventive actions for the observations and is confident of satisfying the USFDA within the stipulated time.
Neuland Laboratories manufactures active pharmaceutical ingredients for global pharmaceutical companies and provides end-to-end solutions for the pharmaceutical industry for chemistry-related services. It supplies to pharmaceutical companies across India, Europe and North America amongst others with a presence in over 85 countries. The company has two manufacturing facilities in Hyderabad, Telangana.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |